# Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR

> **NCT07294495** · NA · NOT_YET_RECRUITING · sponsor: **Shanghai East Hospital** · enrollment: 150 (estimated)

## Conditions studied

- HCM - Hypertrophic Cardiomyopathy

## Interventions

- **DRUG:** Henagliflozin (SGLT2 Inhibitor)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07294495
- **Lead sponsor:** Shanghai East Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-07
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07294495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07294495, "Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07294495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*